TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Navamedic ASA ( (DE:N1A) ).
Navamedic ASA has appointed Nils Ole Krekling as its new Chief Financial Officer, effective January 1, 2026. Krekling’s extensive experience in financial and strategic roles is expected to enhance Navamedic’s financial management and support its strategic goals, potentially impacting the company’s operations and market positioning positively.
More about Navamedic ASA
Navamedic ASA is a Nordic pharmaceutical company focused on enhancing quality of life by supplying high-quality prescription, consumer health, and hospital products through pharmacies and hospitals. The company’s product portfolio addresses significant public health issues like obesity, Parkinson’s disease, antibiotics, and metabolic diseases. Navamedic aims to understand local market needs, making it a preferred partner for international companies seeking to expand in the Nordics and Benelux. The company is listed on the Oslo Stock Exchange and is headquartered in Oslo.
YTD Price Performance: -14.53%
Average Trading Volume: 89,693
Current Market Cap: NOK518M
Learn more about N1A stock on TipRanks’ Stock Analysis page.